Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
ASBNbSvKSS3qw79u
Listen
